Takeda Seeks To Buy Development, Marketing Rights For New Drugs (Japan)
This article was originally published in PharmAsia News
Executive SummaryLooking ahead to 2010, Takeda Pharmaceutical is counting the costs of developing a drug from scratch and looking to partner with other companies for compounds in at least five areas. President Yasuchika Hasegawa says many of its primary drugs face patent expirations, so the firm is looking to buy development and marketing rights for new drugs in areas where the firm's pipeline is lacking, in depression and schizophrenia and irritable bowel syndrome. One urgent quest of Takeda is to find outside sources for lipid-lowering agents since its own TAK-475 faces concerns about side affects. (Click here for more - may require subscription
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.